PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.,Anti-Cancer Drugs

当前位置： X-MOL 学术 › Anti-Cancer Drugs › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Anti-Cancer Drugs ( IF 2.3 ) Pub Date : 2021-09-13 , DOI: 10.1097/cad.0000000000001219
Peter G Rose _{1,

2} , Meng Yao ₃ , Laura M Chambers _{1,

2} , Haider Mahdi _{1,

2} , Robert DeBernardo _{1,

2} , Chad M Michener _{1,

2} , Miriam AlHilli _{1,

2} , Stephanie Ricci _{1,

2} , Roberto Vargas _{1,

2}

Affiliation

To determine the effect of poly-adenosine ribose phosphatase inhibitors (PARPi) on the response to subsequent platinum-based chemotherapy (PBC) in patients with recurrent, platinum-sensitive BRCA-mutated epithelial ovarian, peritoneal, or fallopian cancer (BRCAm EOC).

中文翻译：